Alpha 2.0
Login Register
» Authors » Zi Yi Lim

Zi Yi Lim

Explore the profile of Zi Yi Lim including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 82
Followers 0
Related Specialties
Hematology
General Medicine
Infectious Diseases
Top 10 Co-Authors
Ghulam J Mufti
Wendy Ingram
Antonio Pagliuca
Stephen Devereux
Laurence Pearce
Michelle Kenyon
Aloysius Y L Ho
Chuen Wen Tan
Judith C W Marsh
Ronald Brand
Published In
Br J Haematol
Blood Rev
J Infect
Biol Blood Marrow Transplant
Haematologica
Affiliations
Soon will be listed here.
Recent Articles
1.
Consensus recommendations for optimising the diagnosis and treatment of paroxysmal nocturnal haemoglobinuria in Singapore
Goh Y, Yap E, Tan C, Tan D, Loh Y, Lee Y, et al.
Ann Acad Med Singap . 2024 Jul; 53(6):371-385. PMID: 38979993
Introduction: Paroxysmal nocturnal haemoglobinuria (PNH) is a rare haematologic disease characterised by intravascular haemolysis, thrombophilia and bone marrow failure. There is a lack of established clinical guidance on the screening,...
2.
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes
Krishnamurthy P, Potter V, Barber L, Kulasekararaj A, Lim Z, Pearce R, et al.
Biol Blood Marrow Transplant . 2012 Dec; 19(4):562-8. PMID: 23266740
Relapse occurs in 30%-50% of recipients of T cell-depleted (TCD) reduced-intensity conditioned (RIC) hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Despite limited published...
3.
Real-world experience with posaconazole prophylaxis in high-risk hematological patients in Singapore: a prospective audit
Low C, Ong W, Wong E, Ding Y, Diong C, Jin J, et al.
J Infect . 2012 Dec; 66(3):291-4. PMID: 23201153
No abstract available.
4.
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis
Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, et al.
Haematologica . 2010 Oct; 96(2):291-7. PMID: 20971823
Background: Bone marrow fibrosis in patients with myelodysplastic syndrome is associated with a poor outcome, but whether the outcome after allogeneic stem cell transplantation is related to the degree of...
5.
Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes
Lim Z, Pearce L, Ho A, Barber L, Ingram W, Usai M, et al.
Br J Haematol . 2007 Jul; 138(4):517-26. PMID: 17608767
This prospective study evaluated the kinetics of lymphoid (CD3) engraftment in 110 patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) after allogeneic transplantation and conditioning with fludarabine, busulphan...
6.
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes
Lim Z, Ho A, Ingram W, Kenyon M, Pearce L, Czepulkowski B, et al.
Br J Haematol . 2006 Aug; 135(2):201-9. PMID: 16939494
This prospective study evaluated the outcomes of 75 successive patients receiving a FBC (fludarabine, busulphan, alemtuzumab) reduced-intensity conditioning (RIC) regimen for myelodysplastic syndromes (MDS) using volunteer unrelated donors(VUD). The prognostic...
7.
Allogeneic transplantation for myelodysplastic syndrome (MDS)
Ingram W, Lim Z, Mufti G
Blood Rev . 2006 Jun; 21(2):61-71. PMID: 16759774
Haematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with myelodysplastic syndrome (MDS). Developing conditioning regimens with low toxicity, at the same time as preserving an effective...